Adults using low-dose aspirin for primary or secondary prevention of CVD had lower likelihood of COVID-19 infection versus nonusers<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, March 17, 2021 (HealthDay News) — Aspirin use for cardiovascular disease prevention may also reduce the likelihood of COVID-19 infection, according to a study recently published in the FEBS Journal<\/em>.<\/p>\n Eugene Merzon, M.D., from Leumit Health Services in Tel-Aviv, Israel, and colleagues used data from the Leumit Health Services database to assess outcomes among COVID-19-positive patients (Feb. 1, 2020, to June 30, 2020) using preinfection treatment with low-dose aspirin for primary and secondary prevention of cardiovascular diseases versus nonusers.<\/p>\n The researchers found that aspirin use was associated with a lower likelihood of COVID-19 infection versus nonuse (adjusted odds ratio, 0.71). While aspirin users were older, presented a lower body mass index, and showed a higher prevalence of hypertension, diabetes, and chronic obstructive pulmonary disease than aspirin nonusers, COVID-19 disease duration among aspirin users was significantly shorter versus aspirin nonusers. A higher proportion of patients surviving hospitalization were treated with aspirin, compared to the one patient who died, but this difference was not significant.<\/p>\n “This observation of the possible beneficial effect of low doses of aspirin on COVID-19 infection is preliminary but seems very promising,” a coauthor said in a statement.<\/span><\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n